MX2018009501A - Forma cristalina a de agonista de tlr7, metodo de preparacion y uso de la misma. - Google Patents
Forma cristalina a de agonista de tlr7, metodo de preparacion y uso de la misma.Info
- Publication number
- MX2018009501A MX2018009501A MX2018009501A MX2018009501A MX2018009501A MX 2018009501 A MX2018009501 A MX 2018009501A MX 2018009501 A MX2018009501 A MX 2018009501A MX 2018009501 A MX2018009501 A MX 2018009501A MX 2018009501 A MX2018009501 A MX 2018009501A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline form
- preparation
- tlr7 agonist
- tlr7
- agonist
- Prior art date
Links
- 229940124615 TLR 7 agonist Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- -1 4- (pyrrolidin-1-ylmethyl) benzyl Chemical group 0.000 abstract 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 abstract 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invencion se refiere a una forma cristalina A de un agonista de TLR7 2-butoxi-7-(4-(pirrolidin-1-ilmetil)bencil)-5H-pi rrolo[3,2-d]pirimidin-4-amina (formula I), un método para preparar la forma cristalina A y su uso.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610082029.8A CN107043379A (zh) | 2016-02-05 | 2016-02-05 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| PCT/CN2017/072891 WO2017133684A1 (zh) | 2016-02-05 | 2017-02-04 | 一种tlr7激动剂的晶型a、其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018009501A true MX2018009501A (es) | 2018-12-11 |
| MX374297B MX374297B (es) | 2025-03-06 |
Family
ID=59499348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009501A MX374297B (es) | 2016-02-05 | 2017-02-04 | Forma cristalina a de agonista de tlr7, metodo de preparacion y uso de la misma |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10442811B2 (es) |
| EP (1) | EP3412672B1 (es) |
| JP (1) | JP6889171B2 (es) |
| KR (1) | KR102393280B1 (es) |
| CN (2) | CN107043379A (es) |
| AR (1) | AR107548A1 (es) |
| AU (1) | AU2017215801B2 (es) |
| CA (1) | CA3013518C (es) |
| CL (1) | CL2018002092A1 (es) |
| DK (1) | DK3412672T3 (es) |
| EA (1) | EA035951B1 (es) |
| ES (1) | ES2830443T3 (es) |
| HR (1) | HRP20201644T1 (es) |
| HU (1) | HUE051399T2 (es) |
| IL (1) | IL260968B (es) |
| LT (1) | LT3412672T (es) |
| MX (1) | MX374297B (es) |
| NZ (1) | NZ744884A (es) |
| PH (1) | PH12018501643A1 (es) |
| PL (1) | PL3412672T3 (es) |
| PT (1) | PT3412672T (es) |
| SG (1) | SG11201806683UA (es) |
| SI (1) | SI3412672T1 (es) |
| TW (1) | TWI754629B (es) |
| UA (1) | UA121161C2 (es) |
| WO (1) | WO2017133684A1 (es) |
| ZA (1) | ZA201805186B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| CN107043380A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043379A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| CN107043378A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| WO2019223788A1 (zh) * | 2018-05-25 | 2019-11-28 | 正大天晴药业集团股份有限公司 | 用于治疗肺癌的tlr7激动剂及其药物组合 |
| BR112021015577A8 (pt) | 2019-02-08 | 2021-10-05 | Research & Business Found Sungkyunkwan Univ | Complexo-colesterol agonista do receptor toll-like 7/8, composição de nanopartícula, composição adjuvante, composição de vacina, composição para regular uma função imunológica, composição farmacêutica e uso do complexo |
| EP3937944A1 (en) * | 2019-03-15 | 2022-01-19 | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd | Toll-like receptor agonists for use in the treatment of hepatitis b |
| CN118045051A (zh) * | 2019-04-23 | 2024-05-17 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的固体药物组合物 |
| US20230100429A1 (en) | 2020-03-02 | 2023-03-30 | Progeneer Inc. | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| JP7690222B2 (ja) | 2020-08-04 | 2025-06-10 | プロジェニア インコーポレイテッド | 動力学的制御が可能なアジュバントを含むｍＲＮＡワクチン |
| WO2022031011A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적으로 작용하는 아주번트 앙상블 |
| JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途 |
| CN119431359A (zh) * | 2023-07-28 | 2025-02-14 | 苏州申拓医药科技有限公司 | 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3376479B2 (ja) * | 1991-08-12 | 2003-02-10 | 武田薬品工業株式会社 | 縮合ピリミジン誘導体、その製造法および用途 |
| CN101304748A (zh) * | 2005-08-22 | 2008-11-12 | 加利福尼亚大学董事会 | Tlr激动剂 |
| TW201639852A (zh) | 2008-12-09 | 2016-11-16 | 吉李德科學股份有限公司 | 用於製備可用作類鐸受體調節劑之化合物的中間體化合物 |
| EP2670244B1 (en) * | 2011-02-04 | 2018-04-11 | Duquesne University of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
| EP2800569B1 (en) | 2012-01-05 | 2018-07-25 | Northeastern University | Allosteric modulators of cb1 cannabinoid receptors |
| TR201807076T4 (tr) * | 2012-10-10 | 2018-06-21 | Janssen Sciences Ireland Uc | Viral enfeksiyonların ve diğer hastalıkların tedavisine yönelik pirolo[3,2-d]pirimidin derivatları. |
| EP2922547B1 (en) * | 2012-11-20 | 2017-03-08 | Glaxosmithkline LLC | Novel compounds |
| EP2922550B1 (en) * | 2012-11-20 | 2017-04-19 | Glaxosmithkline LLC | Novel compounds |
| HRP20171150T1 (hr) * | 2012-11-20 | 2017-10-06 | Glaxosmithkline Llc | Novi spojevi |
| ES2877050T3 (es) * | 2014-05-01 | 2021-11-16 | Novartis Ag | Compuestos y composiciones como agonistas del receptor 7 de tipo toll |
| CN106661034B (zh) * | 2014-08-15 | 2019-11-29 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| CN105367576A (zh) | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043379A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
-
2016
- 2016-02-05 CN CN201610082029.8A patent/CN107043379A/zh active Pending
-
2017
- 2017-02-03 TW TW106103695A patent/TWI754629B/zh active
- 2017-02-04 JP JP2018540799A patent/JP6889171B2/ja active Active
- 2017-02-04 LT LTEP17747004.4T patent/LT3412672T/lt unknown
- 2017-02-04 DK DK17747004.4T patent/DK3412672T3/da active
- 2017-02-04 PT PT177470044T patent/PT3412672T/pt unknown
- 2017-02-04 US US16/075,297 patent/US10442811B2/en active Active
- 2017-02-04 WO PCT/CN2017/072891 patent/WO2017133684A1/zh not_active Ceased
- 2017-02-04 HR HRP20201644TT patent/HRP20201644T1/hr unknown
- 2017-02-04 KR KR1020187024627A patent/KR102393280B1/ko active Active
- 2017-02-04 AU AU2017215801A patent/AU2017215801B2/en active Active
- 2017-02-04 CA CA3013518A patent/CA3013518C/en active Active
- 2017-02-04 HU HUE17747004A patent/HUE051399T2/hu unknown
- 2017-02-04 EP EP17747004.4A patent/EP3412672B1/en active Active
- 2017-02-04 ES ES17747004T patent/ES2830443T3/es active Active
- 2017-02-04 SG SG11201806683UA patent/SG11201806683UA/en unknown
- 2017-02-04 CN CN201780009747.5A patent/CN108602831B9/zh active Active
- 2017-02-04 UA UAA201809129A patent/UA121161C2/uk unknown
- 2017-02-04 PL PL17747004T patent/PL3412672T3/pl unknown
- 2017-02-04 SI SI201730461T patent/SI3412672T1/sl unknown
- 2017-02-04 EA EA201891768A patent/EA035951B1/ru not_active IP Right Cessation
- 2017-02-04 NZ NZ744884A patent/NZ744884A/en unknown
- 2017-02-04 MX MX2018009501A patent/MX374297B/es active IP Right Grant
- 2017-02-06 AR ARP170100297A patent/AR107548A1/es not_active Application Discontinuation
-
2018
- 2018-08-01 ZA ZA2018/05186A patent/ZA201805186B/en unknown
- 2018-08-02 IL IL260968A patent/IL260968B/en unknown
- 2018-08-02 PH PH12018501643A patent/PH12018501643A1/en unknown
- 2018-08-03 CL CL2018002092A patent/CL2018002092A1/es unknown
-
2019
- 2019-09-25 US US16/582,575 patent/US10947245B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018009501A (es) | Forma cristalina a de agonista de tlr7, metodo de preparacion y uso de la misma. | |
| MX374300B (es) | Sal de trifluoroacetato de agonista de tlr7 y forma cristalina b de la misma, métodos de preparación y usos. | |
| CY1123729T1 (el) | Αλατα αναστολεα ρι3κ και μεθοδοι για παρασκευη αυτων | |
| UY37927A (es) | Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo | |
| CL2017001930A1 (es) | Derivados de 4h-pirrol[3,2-c]piridin-4-ona | |
| MX2019003605A (es) | Formas solidas de un inhibidor de cdk4/6 selectivo. | |
| MX355428B (es) | Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa. | |
| CO2017004714A2 (es) | Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| UY34104A (es) | ?compuestos derivados benzamídicos heterocíclicos, procesos e intermedios para su preparación, composiciones y métodos para su uso?. | |
| ECSP18010481A (es) | Composiciones de plinabulina | |
| MX391724B (es) | Nuevos derivados de triazolo[4,5-d]pirimidina. | |
| MX374298B (es) | Método para preparar compuesto de pirrolo[3,2-d]pirimidina y sus intermediarios. | |
| MX2019000664A (es) | Preparacion de 14-metil-16-oxabiciclo[10.3.1]pentadecenos de 3-metil-1,5 ciclopentadecanediona. | |
| MX2015013745A (es) | Preparacion de intermediarios de pirimidina utiles para la preparacion de maci tentano. | |
| CR20160016A (es) | Pirazolpiridinas sustituidas | |
| EA201591939A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ АГОНИСТОВ РЕЦЕПТОРА CB2 | |
| PH12018502246A1 (en) | Substituted fused pyrimidinone compounds | |
| IN2013MU00777A (es) | ||
| CO2017002070A2 (es) | Un proceso para la preparación de derivados de 3-fenil/heteroaril-6-fenoxi-8-alquilamino-imidazo[1,2-b] piridazina | |
| MY197130A (en) | Tlr7 agonist crystalline form a, preparation method and use thereof | |
| TH1601003657A (th) | อนุพันธ์ [1,2,4] ไตรอะโซโล [1,5-a]ไพริมิดีน ดังสารยับยั้งโปรเตียโซมของ โปรโตซัวสำหรับการรักษาของโรคที่เกิดจากปรสิต เช่น โรคลิชมาเนียซิส | |
| EA201100683A1 (ru) | Полиморфные формы 5-этокси-2-[2-(морфолино)этилтио]бензимидазол дигидрохлорида и способы их получения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |